AzTrials
AzTrials

Anatomic Stage I Breast Cancer AJCC v8Phase 1NCT04481113

Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer

A Phase 1 study testing Abemaciclib and Niraparib Tosylate Monohydrate in people with Anatomic Stage I Breast Cancer AJCC v8 and Anatomic Stage IA Breast Cancer AJCC v8, run by OHSU Knight Cancer Institute at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This phase I trial tests the side effects and best dose of abemaciclib and niraparib in treating patients with breast cancer that is positive for estrogen or progesterone receptors (hormone receptor positive [HR+]) and HER2 negative. Read more about this study

Who is it for?
Ages 18 years and older
What is being tested?
Abemaciclib and Niraparib Tosylate Monohydrate
Could I receive a placebo?
No, everyone receives an active treatment
How many people
8 participants
Where
1 siteUnited States
Study dates
7 Jun 2021to 20 Jun 2025
Phase
Phase 1
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Ability to understand and the willingness to sign a written informed consent document.
  • Females (regardless of menopausal status), or males
  • Biopsy proven estrogen receptor (ER) and/or progesterone receptor (PR) positive as defined as ER >= 1% and/or PR >= 1% by immunohistochemistry according to American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines for hormone receptor testing
  • HER2 non-amplified per 2018 ASCO/CAP guidelines, defined as:
  • Immunohistochemistry (IHC) score 0/1+, or
  • IHC 2+ and in situ hybridization (ISH) non-amplified with a ratio of HER2 to CEP17 < 2.0, and if reported, average HER2 gene copy number < 4 signals/cells; or
Show all 28Show fewer
  • ISH non-amplified with a ratio of HER2 to CEP17 < 2.0, and if reported, average HER2 gene copy number < 4 signals/cells
  • Clinical T1-T3, any N, M0 invasive breast cancer, by American Joint Committee on Cancer (AJCC) 8th edition clinical staging with the goal being curative intent surgery to completely excise involved tumor in the breast and the draining lymph nodes
  • Individuals with unilateral, multi-focal breast cancer (defined as more than one lesion of invasive breast cancer in the same breast separated from the dominant breast lesion by less than 5 cm of radiologically normal breast tissue) are eligible
  • Participants must be planned for neoadjuvant chemotherapy
  • Except for allowable endocrine therapy up to 4 weeks prior to study enrollment, participants must not have received prior anti-cancer therapy for the treatment of their breast cancer
  • Participant must have disease that is amenable to biopsy, and agree to provide the required research biopsies at baseline, and 2 months after initiating study therapy
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1
  • The participant is able to swallow oral medications
  • Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
  • Platelets >= 100 x 10^9/L
  • Hemoglobin >= 9 g/dL
  • Total bilirubin =< 1.5 x upper limit of normal (ULN). Participants with Gilbert's syndrome with a total bilirubin =< 2.0 times ULN and direct bilirubin within normal limits are permitted
  • Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x ULN
  • If a participant is a cancer survivor, they have undergone potentially curative therapy for all prior malignancies, with no evidence of recurrence > 5 years
  • Female participants of childbearing potential (FOCBP) must have a negative serum or high sensitive urine pregnancy test (per institutional standards) within 7 days prior to the start of study drugs
  • FOCBP must agree to use highly-effective method(s) of contraception during the study and for 6 months after the last dose of study drugs
  • FOCBP are those who have not been surgically sterilized or have not been free from menses for > 1 year without an alternative medical cause
  • Male participants must agree to use an adequate method of contraception starting with the first dose of study therapy through at least 3 months after the last dose of study drugs
  • Participant must agree to not donate blood during the study or for 90 days after the last dose of study treatment
  • Participants receiving corticosteroids may continue as long as their dose is stable for least 4 weeks prior to initiating protocol therapy
  • Participant must agree to not breastfeed during the study or for 30 days after the last dose of study treatment
  • The participant must have normal BP or adequately treated and controlled hypertension (systolic BP <=140 mmHg and diastolic BP ≤90 mmHg).

Who cannot join

  • Prior history of malignancy within 5 years except for successfully treated cervical carcinoma in situ, lobular carcinoma in situ of the breast, or non-melanoma skin cancer
  • Inflammatory breast cancer defined as clinically significant erythema of the breast and/or documented dermal lymphatic invasion (not direct skin invasion by tumor or peau d'orange without erythema) is not eligible
  • Participants that have undergone surgical axillary staging procedure prior to study entry
  • Fine needle aspiration (FNA) or core needle biopsy of axillary node is permitted
  • Bilateral breast cancer, except for those tumors exhibiting similar biomarkers (grade, ER/PR, HER2)
  • Clinical or radiographic evidence of metastatic disease
Show all 30Show fewer
  • Isolated ipsilateral supraclavicular node involvement is permitted
  • A prior history of ductal breast carcinoma in situ (DCIS) treated with contralateral mastectomy and not receiving endocrine therapy is eligible
  • Breast implants are contraindicated only if the implant precludes the required research biopsies or interferes with palpating the breast lesion
  • Prior treatment for this cancer including surgery, radiation therapy, chemotherapy, biotherapy, hormonal therapy or investigational agent prior to study entry
  • Participants may have received up to 4 weeks of endocrine therapy prior to enrollment on trial
  • Participants with myelodysplastic syndrome/acute myeloid leukemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML)
  • Contraindication to undergoing breast and/or axillary lymph node biopsy
  • Contraindication to undergoing surgical resection
  • Prior therapy with a PARP inhibitor
  • Prior therapy with a CDK 4/6 inhibitor
  • The patient has active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [e.g., hepatitis B surface antigen positive]. Screening is not required for enrollment
  • The patient has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance < 30ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline grade 2 or higher diarrhea)
  • Known history of pneumonitis or interstitial lung disease (ILD)
  • Known history of deep vein thrombosis (DVT) or pulmonary embolism (PE)
  • Participant must not have received a transfusion (platelets or red blood cells) =< 4 weeks prior to initiating protocol therapy. Exceptions may be made at the discretion of the investigator for the treatment of clinical complications such as bleeding. In these cases, protocol therapy may start >= 7 days after transfusion
  • Participant must not have received colony stimulating factors (e.g., granulocyte colony-stimulating factor, granulocyte macrophage colony stimulating factor, or recombinant erythropoietin) within 4 weeks prior to initiating protocol therapy
  • The patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest
  • Resting electrocardiogram (ECG) indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (e.g., unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, Fridericia's Correction Formula (QTcF) prolongation > 500 ms, electrolyte disturbances, etc.), or participants with congenital long QT syndrome
  • Uncontrolled hypertension, or hypertension that cannot otherwise be clinically managed before initiating study therapy
  • Psychiatric illness/social situations, or any condition that, in the opinion of the investigator, would: interfere with evaluation of study treatment or interpretation of participant safety or study results, or substantially increase risk of incurring adverse events (AEs), or compromise the ability of the patient to give written informed consent
  • Participant must not have had major surgery =< 3 weeks prior to initiating protocol therapy and participant must have recovered from any surgical effects
  • Hypersensitivity to any study agent, or its excipients, when administered alone
  • Females who are pregnant or lactating
  • Judgment by the investigator that the patient should not participate in the study if the patient is unlikely to comply with study procedures, restrictions and requirements

Trial locations and contacts

1 site in 1 country.

United States1 site

  • OHSU Knight Cancer Institute

    Portland, Oregon, 97239

Other trials in United States

About this study

Official title: A Phase 1 Study of Abemaciclib and Niraparib as Neoadjuvant Therapy in Hormone Receptor Positive (HR+) HER2 Negative (HER2-) Breast Cancer

This phase I trial tests the side effects and best dose of abemaciclib and niraparib in treating patients with breast cancer that is positive for estrogen or progesterone receptors (hormone receptor positive [HR+]) and HER2 negative. Abemaciclib may stop the growth of tumor cells by blocking certain proteins called cyclin-dependent kinases, which are needed for cell growth. PARPs are proteins that help repair DNA mutations. PARP inhibitors, such as niraparib, can keep PARP from working so tumor cells can't repair themselves and grow. Giving abemaciclib and niraparib together before surgery may make the tumor smaller.

Read the detailed description

PRIMARY OBJECTIVES:

  1. To determine the maximum-tolerated dose (MTD) and/or recommended phase 2 dose of the combination of abemaciclib and niraparib tosylate monohydrate (niraparib).

II. To assess safety and tolerability of the combination of abemaciclib and niraparib in early stage HR+ breast cancer.

SECONDARY OBJECTIVES:

  1. To determine clinical response to treatment. II. To determine pathologic response to treatment. III. To determine feasibility of combination as determined by no delay to standard of care breast surgery.

EXPLORATORY OBJECTIVE:

  1. To assess occurrence of secondary myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) malignancy.

OUTLINE: This is a phase 1 dose-escalation study of abemaciclib in combination with niraparib followed by a dose-expansion study.

Patients receive abemaciclib orally (PO) twice daily (BID) and niraparib PO once daily (QD). Treatment repeats every 28 days for up to 2-4 cycles in the absence of disease progression or unacceptable toxicity. Patients who complete 4 cycles undergo standard of care mastectomy or lumpectomy. Patients demonstrating progressive disease after only 2 cycles are switched to receive standard of care chemotherapy prior to undergoing mastectomy or lumpectomy.

Patients are followed up at 30 days after date of surgery, every 3 months for the first 6 months, every 6 months for 2 years, then annually for up to 5 years from date of surgery.

Being tested
Abemaciclib, Niraparib Tosylate Monohydrate
Medical subject headings
Unilateral Breast Neoplasms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AbemaciclibDrug

    Also called LY-2835219, LY2835219, Verzenio

    Given PO

  • Niraparib Tosylate MonohydrateDrug

    Also called Zejula

    Given PO

Study groups in NCT04481113
Study groupRoleWhat they receive
Treatment (abemaciclib, niraparib)ExperimentalPatients receive abemaciclib PO BID and niraparib PO QD. Treatment repeats every 28 days for up to 2-4 cycles in the absence of disease progression or unacceptable toxicity. Patients who complete 4 cycles undergo standard of care mastectomy or lumpectomy. Patients demonstrating progressive disease after only 2 cycles are switched to receive standard of care chemotherapy prior to undergoing mastectomy or lumpectomy.
Receives: Drug: Abemaciclib; Drug: Niraparib Tosylate Monohydrate

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Incidence of dose limiting toxicities (DLTs) for the proposed combination

    Dose-limiting toxicities will specifically be reported for the DLT evaluation period using the MTD-evaluable population.

    Measured: First dose of study agents to end of cycle 1 for dose-determining phase (each cycle is 28 days)

  2. Incidence of adverse events (AEs) and serious AEs for the proposed combination

    Adverse events will be tabulated by the Medical Dictionary for Regulatory Activities (MedDRA version 21.1) preferred term and system organ class and a preferred term. The severity of the AEs will be assessed by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 criteria. Descriptive statistics using the safety evaluable population will be used to report on all on-study AEs, grade 3-4 AEs, treatment-related AEs, grade 3-4 treatment-related AEs, serious adverse events (SAEs), treatment-related SAEs, and AEs leading to discontinuation per CTCAE v5.0. Grade 3-4 laboratory abnormalities will be summarized using worst grade NCI CTCAE v 5.0 criteria.

    Measured: Up to 90 days from last dose of study agent (up to 7 months)

Secondary outcomes (5)

  1. Overall objective response rate (ORR)

    Overall response will be summarized descriptively. ORR will be estimated with 95% confidence interval (CI). The CI will be calculated based on the exact method for binomial distributions.

    Measured: From the date of first dose of study agents to 30 days post-surgery (up to 5 months)

  2. Clinical benefit rate (CBR)

    An estimate of CBR will be measured and reported with 95% exact CI. Participants who achieve a complete response (CR), partial response (PR), or stable disease (SD) for at least 6 months on the current protocol will be qualified as deriving benefit from therapy and will count towards the CBR measurement.

    Measured: From date of dose of study agents to 30 days post-surgery (up to 5 months)

  3. Rate of pathological complete response (pCR)

    pCR will be tabulated as proportions and analyzed descriptively. Rate of delay to breast surgery will be summarized descriptively

    Measured: At time of surgical resection (up to 4 months)

  4. Rate of residual cancer burden (RCB) 0-1

    RCB will be tabulated as proportions and analyzed descriptively. Rate of delay to breast surgery will be summarized descriptively

    Measured: At time of surgical resection (up to 4 months)

  5. Rate of delay to breast surgery

    Defined as proportion of participants with time-to-surgery > 90 days following completion of study therapy due to study-treatment related toxicity.

    Measured: From date of last dose of study drug to date of surgery (up to 4 months)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted22 Jul 2020
  2. Study start7 Jun 2021
  3. Primary completion11 Oct 2023
  4. Study completion20 Jun 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
8 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04481113
Sponsor's protocol ID
STUDY00021243
Other IDs
NCI-2020-03813, STUDY00021243
Status last verified
Apr 2025
First submitted
17 Jul 2020
Last updated
29 Jan 2026
Results posted
No
FDA-regulated drug
Yes
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A Phase 1 study testing Abemaciclib and Niraparib Tosylate Monohydrate in people with Anatomic Stage I Breast Cancer AJCC v8 and Anatomic Stage IA Breast Cancer AJCC v8, run by OHSU Knight Cancer Institute at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 28 inclusion and 30 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Incidence of dose limiting toxicities (DLTs) for the proposed combination (time frame: First dose of study agents to end of cycle 1 for dose-determining phase (each cycle is 28 days)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04481113.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jan 2026.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in